Emergent BioSolutions sees FY13 revenue $311M-$313M, consensus $307.84M. The company also anticipates FY13 GAAP net income of $30M-$32M. Excluding approximately $7M of transaction-related and restructuring costs incurred during the year, the company is providing a forecast for 2013 non-GAAP adjusted net income of $35M-$37M.
News For EBS From The Last 14 Days
Check below for free stories on EBS the last two weeks.